

Accepted Manuscript

Radiocontrast media hypersensitivity: skin testing differentiates allergy from non-allergic reactions and identifies a safe alternative as proven by intravenous provocation

Axel Trautmann, M.D., Knut Brockow, M.D., Valeria Behle, M.D., Johanna Stoevesandt, M.D.

PII: S2213-2198(19)30376-9

DOI: <https://doi.org/10.1016/j.jaip.2019.04.005>

Reference: JAIP 2205

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*


Received Date: 11 November 2018

Revised Date: 10 March 2019

Accepted Date: 1 April 2019

Please cite this article as: Trautmann A, Brockow K, Behle V, Stoevesandt J, Radiocontrast media hypersensitivity: skin testing differentiates allergy from non-allergic reactions and identifies a safe alternative as proven by intravenous provocation, *The Journal of Allergy and Clinical Immunology: In Practice* (2019), doi: <https://doi.org/10.1016/j.jaip.2019.04.005>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 Title page

2 Radiocontrast media hypersensitivity: skin testing differentiates allergy
3 from non-allergic reactions and identifies a safe alternative as proven by
4 intravenous provocation

5 Axel Trautmann, M.D.¹, Knut Brockow, M.D.², Valeria Behle, M.D.¹, and Johanna
6 Stoevesandt, M.D.¹

7 ¹ Department of Dermatology and Allergy, University Hospital Würzburg, Germany

8 ² Department of Dermatology and Allergy, Technical University of Munich, Germany

9 Running head: Radiocontrast media hypersensitivity

10 Correspondence: Axel Trautmann, M.D.
11 Department of Dermatology and Allergy
12 Allergy Center Mainfranken
13 University Hospital Würzburg
14 97080 Würzburg, Germany
15 Tel +49 931 201 26710; Fax +49 931 201 26700
16 E-Mail trautmann_a@ukw.de
17

SUMMARY (239 words)

Background. Hypersensitivity reactions occurring within minutes after intravascular injection of iodinated radiocontrast media (RCM) are common and have been previously considered to be non-allergic. However, in the last decades, evidence is increasing that also genuine RCM allergy may present as either full-blown anaphylaxis or delayed exanthematous skin reaction.

Objectives. We aimed to assess whether allergy diagnostics including skin and provocation testing can differentiate between non-allergic and allergic RCM hypersensitivity by identifying the causative RCM as well as tolerated alternative RCM.

Methods. We retrospectively evaluated clinical and diagnostic data from 45 consecutive patients with RCM hypersensitivity.

Results. Immediate non-allergic RCM hypersensitivity was diagnosed in 21 patients, immediate-type RCM allergy in 11, delayed-type RCM allergy in 11, and delayed-type iodine allergy in two. All patients with immediate-type RCM allergy had a history of moderate to severe anaphylaxis. Eleven of 13 patients with delayed-type allergic reactions including the two cases of iodine allergy suffered from maculopapular exanthem developing several hours to days after exposure, one was a systemic hypersensitivity syndrome and one a fixed drug eruption. Of 18 RCM-allergic patients tested, all tolerated an alternative RCM in the intravenous provocation.

Conclusions. The diagnostic sensitivity of intradermal RCM testing to identify allergic patients is high in both, immediate-type and delayed-type RCM allergy. Intravenous provocation with a skin test-negative RCM is safe and enables identification of a tolerated alternative RCM. Additional skin testing of iodine solution is required to identify patients with iodine allergy.

Key words

anaphylaxis; challenge testing; drug adverse reaction; drug allergy; drug hypersensitivity; exanthem; radiocontrast media

Abbreviations

DRESS, drug rash with eosinophilia and systemic symptoms; MPE, maculopapular exanthem; RCM, radiocontrast media

“highlights box”

What is already known about this topic? Non-allergic hypersensitivity upon injection of iodinated RCM is not rare and can be prevented by premedication. Full-blown anaphylaxis or maculopapular exanthem (MPE) have been increasingly reported to be caused by RCM allergy.

What does this article add to our knowledge? Intradermal testing of 1:10 dilutions of the original RCM solution enables differentiation between non-allergic reactions, immediate-type or delayed-type RCM allergy. Provocation testing regularly identifies an alternative RCM, which can be used in future X-ray examinations.

How does this study impact current management guidelines? Cross-reactivity between different RCM is common, but intravenous provocation with skin test-negative RCM is safe and reliably identifies a tolerated alternative. Iodine allergy is a rare but possibly underestimated cause of RCM-induced MPE.

INTRODUCTION

Non-allergic (not IgE-mediated) hypersensitivity reactions following intravenous injection of iodinated radiocontrast media (RCM) are not uncommon, though the incidence has considerably declined due to the introduction of modern non-ionic and low-osmolar RCM (1). In recent years, increasing evidence shows that genuine (IgE-mediated) RCM allergy is comparatively rare, but is a potential cause of severe clinical reactions and should therefore be diagnosed reliably. Immediate-type, IgE-mediated allergy may be the underlying mechanism of RCM-induced anaphylaxis whereas delayed-type RCM allergy usually manifests as maculopapular exanthem (MPE) occurring within hours or even days after exposure (2-5).

Intradermal testing of diluted RCM solutions is a sensitive test method for both the diagnosis of immediate-type and delayed-type RCM allergy (6, 7). Published data on the diagnostic sensitivity of intradermal RCM testing, however, considerably differ, ranging from less than 50% to more than 90% (7-11). The specificity of intradermal tests with appropriate, that is at least 1:10 dilutions of the original RCM preparation is likewise considered to be very high, thus provocation is recommended with skin test-negative RCM only (6). Patients and laypersons commonly perceive RCM-induced adverse reactions to be equivalent to an iodine allergy. True iodine allergy, however, has been diagnostically confirmed as a cause of RCM-induced MPE on only rare occasions and has even been referred to as “iodine allergy myth” (12, 13).

Clinical and diagnostic data from a cohort of 45 consecutive patients with a convincing history of a RCM-induced immediate or delayed-type hypersensitivity reaction were retrospectively evaluated for the current study. (i) We aimed to accurately differentiate between reactions due to non-allergic mechanisms, immediate-type allergy, and delayed-type allergy. (ii) Skin tests were evaluated in order to identify the culprit and possibly cross-reactive RCM as well as patients reacting to iodine. (iii) Provocation testing was performed

as the gold standard to assess the validity of skin tests as well as to evaluate its ability to identify an alternative RCM, which can be used in future X-ray examinations.

METHODS

Patients. RCM hypersensitivity was diagnosed in 45 patients between January 2008 and August 2018. Collection of data included age and sex, type of radiological examination, and time interval between RCM injection and onset of symptoms. Clinical symptoms were assigned to reaction patterns, that is (i) immediate-type anaphylaxis-like reaction within 15 minutes or (ii) delayed-type reaction more than 6 hours after RCM injection. The severity of anaphylaxis was classified as mild, moderate or severe as explained in **Table 1** (14). We have only recruited patients with at least one objective symptom of anaphylaxis, i.e. generalized urticaria. Unlike previous studies, cases with merely subjective or minor immediate-type reactions, such as itching, flushing, nausea, palpitations or heat sensation, were excluded. Information about the clinical reaction was retrieved from medical records, radiologists, treating physicians, and caregivers when necessary. We additionally recorded the time interval between the clinical reaction and presentation for allergy testing. The institutional review board of the University Hospital Würzburg consented to the retrospective review and publication of anonymized clinical data.

Intradermal RCM testing. Intradermal testing of RCM solutions was performed according to Brockow et al. and invariably included readings at 15 minutes and on days two, three, and four (6). At least three RCM (which are most commonly used by the radiologists in the geographical region of our allergy center) including the culprit RCM were tested in a 1:10 dilution of the original RCM preparation in physiological saline solution. This dilution was always prepared directly before the testing procedure and used within a maximum of one hour. We injected 30-50 μ L of the test solution to produce a bleb of 3-5 mm. A wheal of at least 6 mm diameter with surrounding erythema at 15 minutes reading was assessed as a positive immediate reaction. Wheals measuring 3-5 mm were considered irritative if subsiding on testing at a dilution of 1:100. An erythematous and infiltrated plaque, clearly visible and palpable on days two, three and four was assessed as a positive delayed-type skin test reaction.

Iodine skin testing. In cases with a history of RCM-induced delayed-type MPE, prick and patch tests with iodine tincture (iodine dissolved in a mixture of ethanol and water, resulting in a solution containing approximately 18-22 mg/mL iodine and 21-26 mg/mL sodium iodide) and 2% Lugol's solution (6.6 mg/mL iodine and 13.4 mg/mL potassium iodide in an aqueous solution) were performed in addition to RCM intradermal testing (15). Prick and patch testing was performed and read as described by Brockow et al. and Scherer et al. (6, 12). Clinical relevance of a positive prick or patch test reaction was verified by repeated open application of the aforementioned iodine solutions twice daily for five days onto the outer side of an upper arm.

Intravenous RCM provocation. Provocation with a skin test-negative RCM was performed to exclude RCM allergy and to determine the reliability of a negative skin test. General principles of our provocation protocol were: (i) the time interval since immediate-type reactions was at least four weeks, recovery from MPE was at least eight weeks ago; (ii) written informed consent was obtained from each patient; (iii) prior to RCM injection, renal and thyroid function were examined by measurement of serum creatinine and thyrotropin; (iv) intake of metformin was discontinued 48 hours before RCM injection (16, 17); (v) patients were closely monitored and equipment for emergency treatment was available throughout the entire procedure. Incremental doses were given intravenously every 30 minutes. Patients with a history of anaphylaxis received 0.05, 0.5, 1.0, 5.0, 7.5, 10.0, and 25.0 mL (total 49.05 mL). Patients who reported a delayed-type reaction received 1.0, 5.0, 7.5, 10.0, and 25.0 mL (total 48.5 mL). All patients were observed for at least one hour after the last injection and were advised to present for objective examination if any symptoms developed within the next days.

RESULTS

Clinical data. Non-allergic RCM hypersensitivity was diagnosed in 21 patients, immediate-type allergy in 11, and delayed-type allergy in 13 (**Table 2, Figure 1**). RCM were most commonly administered during urography (15x), coronary angiography (14x), or computed tomography (14x). **Table 2** shows baseline clinical data including the patients' age and sex, incriminated RCM, time interval to onset of symptoms, and clinical signs. The time interval between the RCM-induced hypersensitivity reaction and presentation for allergy testing was less than one year in 37 out of 45 evaluated patients (82.2%).

All 11 patients with immediate-type RCM allergy had a history of moderate to severe anaphylaxis, which occurred within five minutes after RCM injection. In contrast, 20 of the 21 patients with non-allergic hypersensitivity reported only a mild cutaneous reaction, i.e. generalized urticaria. The total 21 skin test-negative patients with non-allergic reactions received a medical document recommending that premedication should be administered before application of iodinated RCM (18).

Of the 13 patients with delayed-type reactions, 11 suffered from MPE. One patient (#LA-9, **Table 3**) was diagnosed with drug-induced hypersensitivity syndrome or DRESS (drug rash with eosinophilia and systemic symptoms) due to a generalized pustular exanthem, facial erythema and edema, fever and hepatitis (maximal glutamate-pyruvate transaminase 736 U/L). Photographic records of circumscribed, erythematous and bullous lesions on the dorsal hands and feet compatible with a multilocular fixed drug eruption were available in another patient (#LA-6, **Table 3**), and post-inflammatory hyperpigmentation of these lesions was still visible at the time of testing. Diagnosis of these clinical variants of non-immediate drug reactions was based on established clinical and laboratory criteria (19, 20).

Intradermal RCM testing. Test results of the 22 patients with RCM allergy are shown in **Table 3**. In late readings at days two, three, and four, all intradermal test results were either clearly positive or negative. Wheal-and-flare reactions at 15 minutes were also almost always

unequivocally positive with a wheal diameter of at least 6 mm and surrounding erythema. A borderline test reaction measuring 4-5 mm was found in the reading at 15 minutes in only two cases when using standard 1:10 dilutions of iopromide and iopamidol, respectively. Subsequent testing of a 1:100 dilution was clearly negative and the initial test reactions were thus considered as irritant or false positive.

Three RCM, namely iopamidol, iopromide and iomeprol, were tested in all patients because they are most commonly used by the referring radiologists within our geographical region (**Table 3**). We observed a certain degree of cross-reactivity between iopromide and iomeprol, while sensitization against iopamidol occurred either isolated (#IM-5, #LA-10) or in patients with broad sensitization to several RCM (#LA-1, #LA-5). An isolated iomeprol allergy was found in seven cases, and one patient was exclusively sensitized against iopromide (#IM-8). There was a tendency towards a broader sensitization pattern among patients with delayed-type reactions compared to those with immediate reactions.

In the patient reporting an iobitridol-induced fixed drug eruption (#LA-6), diagnostic intradermal testing with RCM was only positive within the areas of former lesions.

Cases of iodine allergy. Two patients had a clear-cut history of MPE approximately 12 hours after injection of iomeprol during coronary angiography and computed tomography, respectively. Alternative causes including viral or bacterial infections or other drugs could be ruled out. Unexpectedly, intradermal testing including the culprit RCM was consistently negative. Prick testing of iodine tincture, however, revealed an unequivocally positive, erythematous and infiltrated skin reaction on days three and four in both patients. Prick testing with 2% Lugol's solution was negative. Subsequent open epicutaneous application of iodine tincture twice daily for five days provoked an acute allergic contact dermatitis. Additional oral provocation with Lugol's solution was rejected by both patients. Skin testing with these iodine solutions were invariably negative in all other 11 patients with a history of RCM-induced MPE.

Intravenous RCM provocation. Of the 22 patients with RCM allergy, all 18 tested patients tolerated intravenous provocation with a skin test negative RCM (**Figure 1, Table 3**). Iopamidol was identified as a tolerated alternative in 10 patients, iomeprol and iobitridol were tolerated in three patients each, and iopromide in two (**Table 3**). Patient #IM-4 tolerated iopamidol in the context of controlled provocation testing, and skin test negative iobitridol was given and tolerated during a mandatory radiological examination. Four patients rejected provocation testing.

DISCUSSION

In accordance with previous publications, our data demonstrate that non-allergic RCM hypersensitivity is a common cause of mild anaphylactic reactions presenting as a pruritic flush, urticaria and/or angioedema but without any significant cardiovascular or respiratory symptoms (1-3, 9). In those patients, diagnostic skin testing is uniformly negative. The pathogenesis of non-allergic RCM hypersensitivity is still unsolved. Direct histamine liberating effects of RCM and non-specific complement activation have been discussed (21). Non-allergic hypersensitivity reactions are commonly attenuated if lower RCM doses are given or injection rates are reduced. Premedication with H₁ antihistamines and glucocorticoids may even completely suppress clinical symptoms (13, 17, 18).

In contrast, we believe the data support the position that immediate-type RCM allergy causes moderate to severe anaphylaxis (3, 5, 9). These reactions are most likely IgE-mediated, even if there is only indirect evidence of RCM-directed IgE antibodies as indicated by positive results of intradermal and basophil activation testing (3, 5). IgE antibodies to individual ionic RCM were detected in small quantities (22, 23). Attempts to demonstrate specific IgE binding to modern non-ionic RCM failed due to difficulties to link the chemically inert RCM to a carrier (5).

Delayed-type hypersensitivity reactions occur within hours to days after injection of iodinated RCM and usually present as MPE, which is probably caused by activated T-cells (5, 24). Variants of non-immediate drug reactions including flexural exanthem or systemic hypersensitivity were occasionally described (25, 26). RCM, however, do not belong to the common causes of drug-induced hypersensitivity syndrome, also referred to as DRESS (20, 26). In our series, DRESS was diagnosed in one patient who developed a widespread and severe exanthem accompanied by significant hepatitis within a few days after injection of iomeprol. Our cohort additionally includes a fixed drug eruption following exposure to iobitridol. Intradermal testing of the culprit RCM was only positive within formerly affected skin areas, as is typical for this entity (19).

In order to prevent false positive test reactions, intradermal testing of iodinated RCM requires dilutions of at least 1:10, meaning that test concentrations should not exceed 10% of the concentration used for radiological diagnostics (6). As irritant reactions are strongly dose-dependent, any borderline wheal-and-flare reaction should be verified by additional testing of a 1:100 dilution (27). Allergic test reactions are expected to persist or only slightly decrease upon further dilution, whereas irritant reactions are no longer detectable.

The sensitivity of skin testing with iodinated RCM for the detection of immediate or delayed-type RCM is commonly reported to be high which was explained by the fact that RCM are not subject to any biotransformation (28, 29). Previously published sensitivity rates, however, considerably differ, ranging from less than 50% to more than 90% (7-11). The sensitivity of intradermal testing both *in general* as well as in the diagnostics of RCM allergy obviously depends on accurate execution and experience of the examiner (6, 27). A late test reaction, for example, may be missed if readings are not performed on at least two or better three consecutive days. Moreover, the injection-induced bleb correlates with the injected volume and should measure 3-5 mm (6). The sensitivity of intradermal testing may be impaired if the injected volume is too small. The manufacturer guarantees stable concentrations of iodinated RCM in unopened packages prior to the expiration date. Understandably enough, there are no available data regarding the stability of 1:10 RCM solutions for allergy testing. It is quite possible that the absolute quantity of the active ingredient does not remain stable upon dilution and may decrease as a result of physicochemical reactions and/or interaction with the material of syringes (30). Consequently, diluted RCM solutions should be prepared immediately before testing and used within one hour. Prior to each injection, the solution within the syringe ought to be checked for signs of precipitation or inhomogeneity to be replaced if necessary.

Several groups reported on the detection of RCM-specific sensitization by cellular tests, i.e. basophil activation or lymphocyte transformation (3, 24). These methods, however, are only available in specialized laboratories and cannot be recommended for routine diagnostic use.

Controlled provocation testing of skin-test negative RCM was proposed as final proof of tolerance (2, 5). However, a recent international consensus document dealing with controversial issues of RCM hypersensitivity noticed that there is no generally accepted standard for provocation testing (31). As specified above, total doses of approximately 50 mL RCM solution were administered within 2-3 hours in our cohort. In other studies varying amounts of iodinated RCM (10-100 mL) were injected on a single day or incrementally increased over several days (7, 8, 32, 33). In comparison, 100-150 mL of a RCM solution with iodine strength of 300 mg/mL are estimated for full body computed tomography, 1-1.5 mL/kg body weight for urography. The dose of the provocation test in our study is thus within the lower limit of a typical dose used for an X-ray procedure. Moreover, as the minimum amount of an allergen required to induce a clinically apparent reaction supposedly ranges at low or even very low dose levels, a dose of approximately 50 mL should reliably trigger a reaction in an individual sensitized to RCM (34). In our series, provocation with skin test-negative RCM was invariably tolerated which confirms the excellent sensitivity of intradermal testing in patients with RCM allergy.

Previous studies assessing RCM-induced hypersensitivity considerably differ with regard to the substance panels included for testing and the most commonly identified causes of RCM allergy (7-11). These differences presumably reflect regional standards regarding the choice of RCM for radiological diagnostics. Immunological cross-reactivity between RCM is commonly observed, reported proportions of patients with cross-reactions range from 20% up to 75% (6-10). In our cohort of 22 patients with RCM allergy, sensitization to only one RCM was detected in 11 patients, six of whom, however, were tested with only three different RCM. No uniform or reproducible pattern of cross-reactivity between individual RCM can be deduced from the available literature, and structural formulas of individual RCM do not permit to predict immunological cross-reactivity. Iodinated RCM are monomeric or dimeric derivatives of tri-iodobenzoic acid with different organic side chains attached to the central benzene ring. Chemical structures of these side chains, however, are very similar, and any two-dimensional formula can only imperfectly depict the complex three-dimensional

conformation recognized by an IgE antibody. There is some evidence that iobitridol has a comparatively low tendency to cross-react with other RCM (7, 8, 11, 35). Of the total 16 patients sensitized to iomeprol in our study group, only two were co-sensitized to iopamidol. This observation stands in some contrast to the recent study by Lerondeau et al. assigning both iomeprol and iopamidol into one subgroup of potentially cross-reactive RCM (32).

The iodine molecule effectively absorbs X-rays, but is too toxic for diagnostic use in its inorganic form. In currently used RCM, it is covalently bound to the central benzene ring resulting in a calculated iodine concentration of 150-350 mg/mL (29). RCM solutions contain small quantities of free iodide (up to 50 µg/mL immediately after production) which tend to increase during shelf-life due to de-iodization of the benzene ring (36). The RCM molecule is subject to further de-iodization in the human body. The resulting iodide load by far exceeds the recommended daily intake of 150-200 µg and may trigger incident hyperthyroidism (16, 37). Iodine allergy as cause of RCM hypersensitivity is nonetheless considered to be exceedingly rare and has even been referred to as "iodine allergy myth" (13, 38). Our current series and previous reports, however, demonstrate that RCM-induced MPE may occasionally be triggered by free iodine or iodide rather than by the RCM molecule itself (12). Our two patients reliably tolerated iodine-rich foods including seafood and iodized salt as well as topical application of povidone iodine-based antiseptics. Edible seaweeds such as kelp or *wakame* which are commonly consumed in Japan and contain extreme amounts of iodide may nonetheless cause exanthematous skin reactions in sensitized individuals (39). These observations suggest that the clinical response depends on the iodine dose, way of contact, and possibly on the redox state of iodine. Standard doses of any (though skin test-negative) RCM are very likely to provoke recurring MPE in these iodine sensitive patients.

Conclusions

- i. Anaphylaxis-like reactions occurring within minutes after injection of iodinated RCM may result from either non-allergic hypersensitivity or presumed genuine IgE-mediated allergy.
- ii. Non-allergic hypersensitivity reactions are generally mild with symptoms remaining confined to the skin and premedication is recommended to prevent future reactions. IgE-mediated RCM allergy, on the other hand, causes moderate to severe anaphylaxis with considerable respiratory, cardiovascular, and gastrointestinal involvement.
- iii. Non-immediate RCM hypersensitivity commonly causes MPE with an onset hours to days after exposure and may occasionally trigger other variants of drug reactions including flexural exanthem, fixed drug eruption, or systemic hypersensitivity syndrome (DRESS).
- iv. Intradermal testing of RCM at dilutions of 1:10 may be an appropriate method for the diagnosis of RCM allergy.
- v. Intravenous provocation with a skin-test negative RCM as final proof of tolerance appears safe in both delayed and immediate-type RCM allergy and may someday become the gold standard.
- vi. Iodine allergy is an occasional and possibly under-diagnosed cause of RCM-induced MPE and cannot be detected by intradermal testing of RCM. Additional prick, patch, and open application testing of iodine tincture is required for the detection of iodine allergy.

Author contributions

AT initiated data evaluation; AT, KB, VB, and JS analyzed and interpreted the data; AT wrote the first draft of the article; AT, KB, VB, and JS revised and edited the manuscript and approved the final version.

Funding

The authors have no funding relationships to declare.

Conflict of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

Authors thank Petra Pfeuffer and Petra Raith for their unfailing technical assistance since 25 years.

342 **Table 1.** Grading the severity of anaphylaxis.

severity	symptoms
mild: predominately skin and subcutaneous tissue; negligible to minor systemic symptoms	generalized urticaria with or without angioedema, throat tightness, tachycardia, mild abdominal discomfort
moderate: features of considerable respiratory, cardiovascular or gastrointestinal involvement	dysphonia or hoarseness, deep cough or wheezing, hypotension (systolic blood pressure <90 mmHg in adults), abdominal cramps, vomiting, somnolence, confusion, impaired vision
severe: hypoxia, shock, and severe neurological compromise	stridor, cyanosis, loss of sphincter control, syncope (loss of consciousness), respiratory and cardiac arrest

343

344

345 **Table 2.** Patient cohort. na, not applicable.

	non-allergic (not IgE-mediated) hypersensitivity (n=21)	immediate-type (IgE-mediated) allergy (n=11)	delayed-type (T cell-mediated) allergy (n=13)	
males / females	5 / 16	4 / 7	6 / 7	
median age (range)	55 (20 – 79)	61 (46 – 77)	58 (44 – 80)	
radiological examination				
coronary angiography	3	6	5	
computed tomography	7	2	5	
urography	10	3	2	
phlebography	1	0	1	
incriminated RCM				
iopamidol	0	1	1	
iopromide	7	4	0	
iomeprol	10	6	9	
iobitridol	4	0	1	
iohexol	0	0	1	
iodixanol	0	0	1	
latency time from RCM administration to first symptoms				
< 1 minute	4	1	na	
1 to 5 minutes	10	10	na	
6 to 15 minutes	7	0	na	
6 to 12 hours	na	na	4	
1 to 2 days	na	na	7	
3 days	na	na	2	
clinical signs				
delayed skin reaction	maculopapular exanthem	na	na	11
	systemic hypersensitivity (DRESS)	na	na	1
	fixed drug eruption	na	na	1
anaphylaxis	mild	20	0	na
	moderate	1	6	na
	severe	0	5	na
time interval between RCM-induced reaction and allergy testing				
< 6 months	5	8	10	
6 to 12 months	10	2	2	
> 1 to 5 years	6	1	1	

346

347

Table 3. Results of skin and provocation testing. MPE, maculopapular exanthem; nd, not done.

intradermal skin testing									
patient	incriminated RCM	clinical reaction	iopamidol	iopromide	iomeprol	iobitridol	iohexol	iodixanol	tolerated intravenous provocation
cases with immediate-type RCM allergy									
		severity of anaphylaxis	wheal-and-flare reaction at 15 minutes						
#IM-1	iopromide	severe	–	+	–	+	–	–	iomeprol
#IM-2	iopromide	severe	–	+	+	–	–	–	iopamidol
#IM-3	iopromide	severe	–	+	+	–	–	–	iopamidol
#IM-4	iomeprol	severe	–	+	+	–	–	–	iopamidol and iobitridol
#IM-5	iopamidol	moderate	+	–	–	nd	nd	nd	nd
#IM-6	iomeprol	moderate	–	–	+	–	–	–	iopamidol
#IM-7	iomeprol	moderate	–	–	+	–	+	–	iobitridol
#IM-8	iopromide	severe	–	+	–	–	nd	nd	iobitridol
#IM-9	iomeprol	moderate	–	+	+	–	–	–	iopamidol
#IM-10	iomeprol	moderate	–	–	+	nd	nd	nd	iopamidol
#IM-11	iomeprol	moderate	–	–	+	–	–	–	iopamidol
cases with delayed-type RCM allergy									
			red infiltrated plaque at days 2 - 4						
#LA-1	iomeprol	MPE	+	+	+	–	+	+	nd
#LA-2	iomeprol	MPE	–	+	+	nd	nd	nd	nd
#LA-3	iodixanol	MPE	–	–	–	nd	nd	+	iopamidol
#LA-4	iomeprol	MPE	–	–	+	nd	nd	nd	iopromide
#LA-5	iohexol	MPE	+	+	+	–	+	+	iobitridol
#LA-6	iobitridol	fixed drug eruption	–	+	–	+	nd	nd	iopamidol
#LA-7	iomeprol	MPE	–	–	+	nd	nd	nd	iopamidol
#LA-8	iomeprol	MPE	–	–	+	–	nd	nd	nd
#LA-9	iomeprol	systemic hypersensitivity	–	–	+	nd	nd	nd	iopromide
#LA-10	iopamidol	MPE	+	–	–	nd	nd	nd	iomeprol
#LA-11	iomeprol	MPE	–	+	+	nd	nd	nd	iomeprol

352 **Figure legend**

353 **Figure 1** Results of allergy testing in 45 patients with RCM hypersensitivity.

354

REFERENCES

- 1 Meth M J, Maibach H I. Current understanding of contrast media reactions and implications for clinical management. *Drug Safety* 2006;29:133-141.
- 2 Brockow K, Christiansen C, Kanny G, Clement O, Barbaud A, Bircher AJ, et al. Management of hypersensitivity reactions to iodinated contrast media. *Allergy* 2005;60:150-158.
- 3 Trcka J, Schmidt C, Seitz CS, Bröcker EB, Gross GE, Trautmann A. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? *American Journal of Roentgenology* 2008;190:666-670.
- 4 Seitz CS, Pfeuffer P, Raith P, Bröcker EB, Trautmann A. Radiocontrast media-associated exanthema: identification of cross-reactivity and tolerability by allergologic testing. *European Journal of Radiology* 2009;72:167-171.
- 5 Brockow K. Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? *Immunology and Allergy Clinics of North America* 2009;29:453-468.
- 6 Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, Bonadonna P, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. *Allergy* 2009;64:234-241.
- 7 Torres MJ, Gomez F, Dona I, Rosado A, Mayorga C, Garcia I, et al. Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media. *Allergy* 2012;67:929-935.
- 8 Vernassiere C, Trechot P, Commun N, Schmutz JL, Barbaud A. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. *Contact Dermatitis* 2004;50:359-366.
- 9 Morales-Cabeza C, Roa-Medellin D, Torrado I, DeBarrio M, Fernandez-Alvarez C, Montes-Acenero JF, et al. Immediate reactions to iodinated contrast media. *Annals of Allergy, Asthma and Immunology* : official publication of the American College of Allergy, Asthma, & Immunology 2017;119:553-557.
- 10 Schrijvers R, Breynaert C, Ahmedali Y, Bourrain JL, Demoly P, Chiriac AM. Skin testing for suspected iodinated contrast media hypersensitivity. *Journal of Allergy and Clinical Immunology in Practice* 2018;6:1246-1254.
- 11 Caimmi S, Benyahia B, Suau D, Bousquet-Rouanet L, Caimmi D, Bousquet PJ, et al. Clinical value of negative skin tests to iodinated contrast media. *Clinical and Experimental Allergy* 2010;40:805-810.
- 12 Scherer K, Harr T, Bach S, Bircher AJ. The role of iodine in hypersensitivity reactions to radio contrast media. *Clinical and Experimental Allergy* 2010;40:468-475.
- 13 Böhm I, Nairz K, Morelli JN, Keller PS, Heverhagen JT. Iodinated contrast media and the alleged "iodine allergy": an inexact diagnosis leading to inferior radiologic management and adverse drug reactions. *Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin* 2017;189:326-332.
- 14 Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G, et al. The management of anaphylaxis in childhood: position paper of the European Academy of Allergy and Clinical Immunology. *Allergy* 2007;62:857-871.

- 397 15 <https://en.wikipedia.org> (last access September 14, 2018).
- 398 16 Thomsen HS. Contrast media safety-an update. *European Journal of Radiology*
399 2011;80:77-82.
- 400 17 Rose TA, Choi JW. Intravenous imaging contrast media complications: the basics that
401 every clinician needs to know. *American Journal of Medicine* 2015;128:943-949.
- 402 18 Greenberger PA, Patterson R. The prevention of immediate generalized reactions to
403 radiocontrast media in high-risk patients. *Journal of Allergy and Clinical Immunology*
404 1991;87:867-872.
- 405 19 Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis,
406 and management. *Southern Medical Journal* 2014;107:724-727.
- 407 20 Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity
408 syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting
409 drug. *Immunology and Allergy Clinics of North America* 2009;29:481-501.
- 410 21 Laroche D, Vergnaud MC, Lefrancois C, Hue S, Bricard H. Anaphylactoid reactions to
411 iodinated contrast media. *Academic Radiology* 2002;9 (suppl 2):431-432.
- 412 22 Mita H, Tadokoro K, Akiyama K. Detection of IgE antibody to a radiocontrast medium.
413 *Allergy* 1998;53:1133-1140.
- 414 23 Laroche D, Aimone-Gastin I, Dubois F, Huet H, Gerard P, Vergnaud MC, et al.
415 Mechanisms of severe, immediate reactions to iodinated contrast material. *Radiology*
416 1998;209:183-190.
- 417 24 Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, et al. T cell-mediated
418 reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests.
419 *Journal of Allergy and Clinical Immunology* 2005;115:179-185.
- 420 25 Arnold AW, Häusermann P, Bach S, Bircher AJ. Recurrent flexural exanthema (SDRIFE
421 or baboon syndrome) after administration of two different iodinated radio contrast media.
422 *Dermatology* 2007;214:89-93.
- 423 26 Belhadjali H, Bouzgarrou L, Youssef M, Njim L, Zili J. DRESS syndrome induced by
424 sodium meglumine ioxitalamate. *Allergy* 2008;63:786-787.
- 425 27 Kränke B, Aberer W. Skin testing for IgE-mediated drug allergy. *Immunology and Allergy*
426 *Clinics of North America* 2009;29:503-516.
- 427 28 Rosati G. Clinical pharmacology of iomeprol. *European Journal of Radiology* 1994;18
428 (suppl 1):51-60.
- 429 29 Bourin M, Jolliet P, Ballereau F. An overview of the clinical pharmacokinetics of x-ray
430 contrast media. *Clinical Pharmacokinetics* 1997;32:180-193.
- 431 30 Newton DW. Drug incompatibility chemistry. *American Journal of Health-System*
432 *Pharmacy* 2009;66:348-357.
- 433 31 Sanchez-Borges M, Aberer W, Brockow K, Celik GE, Cernadas J, Greenberger PA, et al.
434 Controversies in drug allergy: radiographic contrast media. *Journal of Allergy and Clinical*
435 *Immunology in Practice* 2019;7:61-65.

- 436 32 Lerondeau B, Trechot P, Waton J, Poreaux C, Luc A, Schmutz JL, et al. Analysis of cross-
437 reactivity among radiocontrast media in 97 hypersensitivity reactions. *Journal of Allergy*
438 and *Clinical Immunology* 2016;137:633-635.
- 439 33 Sese L, Gaouar H, Autegarden JE, Alari A, Amsler E, Vial-Dupuy A, et al. Immediate
440 hypersensitivity to iodinated contrast media: diagnostic accuracy of skin tests and
441 intravenous provocation test with low dose. *Clinical and Experimental Allergy*
442 2016;46:472-478.
- 443 34 Finkelman FD, Rothenberg ME, Brandt EB, Morris SC, Strait RT. Molecular mechanisms
444 of anaphylaxis: lessons from studies with murine models. *Journal of Allergy and Clinical*
445 *Immunology* 2005;115:449-457.
- 446 35 Hasdenteufel F, Waton J, Cordebar V, Studer M, Collignon O, Luyasu S, et al. Delayed
447 hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22
448 patients. *Journal of Allergy and Clinical Immunology* 2011;128:1356-1357.
- 449 36 VanDerMolen AJ, Thomsen HS, Morcos SK. Effect of iodinated contrast media on thyroid
450 function in adults. *European Radiology* 2004;14:902-907.
- 451 37 Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast
452 media exposure and incident hyperthyroidism and hypothyroidism. *Archives of Internal*
453 *Medicine* 2012;172:153-159.
- 454 38 Westermann-Clark E, Pepper AN, Talreja N, Lockey RF. Debunking myths about "allergy"
455 to radiocontrast media in an academic institution. *Postgraduate Medicine* 2015;127:295-
456 300.
- 457 39 Kubota Y, Koga T, Nakayama J. Iodine allergy induced by consumption of iodine-
458 containing food. *Contact Dermatitis* 2000;42:286-287.

